Immunosuppressive Therapy Alone Versus Plus Oral Anticoagulation in the Treatment of VT Associated With Behcet's Disease

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 110 participants.

Also called NCT06925698

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 110 participants (planned count) (from the registry)
Sponsor
Marmara University (from the registry)
Registry
  • NCT NCT06925698
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Türkiye (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT06925698. Randomized; quadruple masking; primary purpose treatment. Start 2025-04-30 (anticipated); primary completion 2027-04-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Immunosuppressive Therapy Alone Versus Plus Oral Anticoagulation in the Treatment of VT Associated With Behcet's Disease
Acronym
BETTER
Condition
Behcet Disease
Condition
Behcet Disease and Vascular Involvement
Condition
Deep Venous Thromboses
Condition
Post Thrombotic Syndrome
Intervention (Drug)
Placebo plus immunosuppression
Intervention (Drug)
Rivaroxaban plus immunosupression
Lead sponsor
Marmara University (class: other)
Collaborator
Health Institutes of Turkey (class: other government)

Record details

Record id
cardio:ct-nct06925698
Content hash
a485f690091e60c65bee22af12c318c52464dfa3ec4992d6c2ed48811a6b3139